Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities: 2024

Historic Total Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 1 years, with Dec 2024 value amounting to $109.0 million.

  • Crinetics Pharmaceuticals' Total Non-Current Liabilities rose 16.45% to $121.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year increase of 16.45%. This contributed to the annual value of $109.0 million for FY2024, which is N/A change from last year.
  • Crinetics Pharmaceuticals' Total Non-Current Liabilities amounted to $109.0 million in FY2024.
  • In the past 5 years, Crinetics Pharmaceuticals' Total Non-Current Liabilities registered a high of $109.0 million during FY2024, and its lowest value of $109.0 million during FY2024.
  • Its 1-year average for Total Non-Current Liabilities is $109.0 million, with a median of $109.0 million in 2024.